Sutro Biopharma, Inc. (STRO)
Market Closed
17 Jul, 20:00
$
23. 57
-0.16
-0.6743%
$
287.7M Market Cap
- P/E Ratio
- Div Yield
330,700 Volume
-3.14 Eps
$ 23.73
Previous Close 
Want to track STRO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments.
Seekingalpha | 1 year ago
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
Zacks | 1 year ago
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.64 per share a year ago.
Zacks | 1 year ago
